牛磺酸上调基因1和微小RNA-145在胃癌中的表达关系研究

doi:10.3877/cma.j.issn.1674-0793.2020.04.011

目的

检测牛磺酸上调基因1（TUG1）和微小RNA-145（miR-145）在胃癌中的表达情况，探讨两者在胃癌发病中的作用及关系。

方法

选取2016年2月至2017年2月于海南省肿瘤医院行根治性胃切除术的局部进展期胃癌患者110例，采用实时荧光定量-聚合酶链反应（RT-PCR）方法检测胃癌组织和癌旁正常组织中TUG1、miR-145的相对表达量，分析TUG1、miR-145表达相关性及其与临床病理资料、术后生存的关系。

结果

与正常组织相比，胃癌组织中TUG1的表达明显升高（P<0.05），miR-145的表达明显降低（P<0.05）。胃癌组织中TUG1、miR-145的相对表达量呈明显负相关关系（P<0.05）。TUG1的表达水平与胃癌患者的淋巴结转移、肿瘤分化程度、临床分期有关（P<0.05），miR-145的表达水平与胃癌患者的淋巴结转移、临床分期有关（P<0.05）。TUG1低表达的胃癌患者总生存率明显高于TUG1高表达者（P=0.010），miR-145高表达胃癌患者总生存率明显高于miR-145低表达者（P<0.001）。

结论

在胃癌组织中，TUG1明显高表达，miR-145明显低表达，且两者呈负相关关系，具有判断胃癌预后的价值。

关键词: 胃肿瘤, 微RNAs, 牛磺酸上调基因1, miRNA-145

Objective

To detect the expression of taurine up-regulated gene 1 (TUG1) and microRNA-145 (miR-145) in gastric cancer, and to explore their role and relationship in the pathogenesis of gastric cancer.

Methods

From February 2016 to February 2017, 110 cases of gastric cancer underwent radical operation in Hainan Cancer Hospital were selected, the gastric cancer tissues of the patients were taken as the study samples, and the normal tissues beside the cancer were taken as the control samples, the relative expressions of TUG1 and miR-145 in gastric cancer tissue and paracancerous normal tissue were detected by real-time fluorescence quantitative PCR. The relationships between the expressions of TUG1 and miR-145and the clinicopathological data, and the correlation between the relative expressions of TUG1 andmiR-145 and the postoperative survival were analyzed.

Results

Compared with normal tissues, the expression of TUG1 was significantly increased in gastric cancer tissues (P<0.05), the expression of miR-145decreased significantly (P<0.05). There was a negative correlation between the relative expression of TUG1 and miR-145 in gastric cancer (P<0.05). There were significant differences in lymph node metastasis, tumor differentiation and clinical stage between the TUG1 high expression group and the TUG1 low expression group (P<0.05). The expression level of miR-145 was related to lymph node metastasis and clinical stage of patients with gastric cancer (P<0.05). The overall survival rate of gastric cancer patients with TUG1 low expression was significantly higher than that of patients with TUG1 high expression(P=0.010), and the overall survival rate of gastric cancer patients with miR-145 low expression of was significantly lower than that of patients with miR-145 high expression (P<0.001).

Conclusion

TUG1 is significantly highly expressed in gastric cancer, miR-145 is significantly highly expressed in gastric cancer, they are negatively correlated, and have the value of predicting the prognosis of gastric cancer.

Key words: Stomach neoplasms, MicroRNAs, Taurine upregulated gene 1, miRNA-145

图3 miR-145表达与胃癌患者的生存关系

表1 TUG1和miR-145表达及其与胃癌临床病理特征的关系（例）

临床病理特征		例数	TUG1高表达(80例)	TUG1低表达(30例)	χ2值	P值	miR-145高表达(22例)	miR-145低表达(88例)	χ2值	P值
性别		?	?	?	0.307	0.579	?	?	0.235	0.628
?	男	65	46	19	?	?	12	53	?	?
?	女	45	34	11	?	?	10	35	?	?
年龄(岁)		?	?	?	0.154	0.695	?	?	0.453	0.501
?	>60	48	34	14	?	?	11	37	?	?
?	≤60	62	46	16	?	?	11	51	?	?
肿瘤大小(cm)		?	?	?	1.650	0.199	?	?	2.045	0.153
?	>5	55	43	12	?	?	8	47	?	?
?	≤5	55	37	18	?	?	14	41	?	?
淋巴结转移		?	?	?	8.142	0.004	?	?	5.729	0.017
?	无	60	37	23	?	?	17	43	?	?
?	有	50	43	7	?	?	5	45	?	?
肿瘤分化程度		?	?	?	4.830	0.028	?	?	0.453	0.501
?	低	62	40	22	?	?	11	51	?	?
?	高	48	40	8	?	?	11	37	?	?
TNM分期		?	?	?	13.406	<0.001	?	?	12.462	<0.001
?	Ⅰ~Ⅱ	53	30	23	?	?	18	35	?	?
?	Ⅲ~Ⅳ	57	50	7	?	?	4	53	?	?

表1 TUG1和miR-145表达及其与胃癌临床病理特征的关系（例）

临床病理特征		例数	TUG1高表达(80例)	TUG1低表达(30例)	χ2值	P值	miR-145高表达(22例)	miR-145低表达(88例)	χ2值	P值
性别		?	?	?	0.307	0.579	?	?	0.235	0.628
?	男	65	46	19	?	?	12	53	?	?
?	女	45	34	11	?	?	10	35	?	?
年龄(岁)		?	?	?	0.154	0.695	?	?	0.453	0.501
?	>60	48	34	14	?	?	11	37	?	?
?	≤60	62	46	16	?	?	11	51	?	?
肿瘤大小(cm)		?	?	?	1.650	0.199	?	?	2.045	0.153
?	>5	55	43	12	?	?	8	47	?	?
?	≤5	55	37	18	?	?	14	41	?	?
淋巴结转移		?	?	?	8.142	0.004	?	?	5.729	0.017
?	无	60	37	23	?	?	17	43	?	?
?	有	50	43	7	?	?	5	45	?	?
肿瘤分化程度		?	?	?	4.830	0.028	?	?	0.453	0.501
?	低	62	40	22	?	?	11	51	?	?
?	高	48	40	8	?	?	11	37	?	?
TNM分期		?	?	?	13.406	<0.001	?	?	12.462	<0.001
?	Ⅰ~Ⅱ	53	30	23	?	?	18	35	?	?
?	Ⅲ~Ⅳ	57	50	7	?	?	4	53	?	?

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]	Gao M, Yin H, Fei ZW. Clinical application of microRNA in gastric cancer in Eastern Asian area[J]. World J Gastroenterol, 2013, 19(13): 2019-2027.
[3]	Sant M, Minicozzi P, Primic-Žakelj M, et al. Cancer survival in Europe, 1999-2007: doing better, feeling worse?[J]. Eur J Cancer, 2015, 51(15): 2101-2103.
[4]	Zhou Y, Lu Y, Li R, et al. Prognostic role of long non-coding RNA TUG1 expression in various cancers: A Meta-analysis[J]. Oncotarget, 2017, 8(59): 100499-100507.
[5]	Cui XB, Li S, Li TT, et al. Targeting oncogenic PLCE1 by miR-145 impairs tumor proliferation and matastasis of esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(2): 1777-1795.
[6]	郗洪庆，张珂诚，卫勃, 等. 胃癌TNM分期第八版更新在临床诊断治疗中的意义和思考[J]. 中华胃肠外科杂志, 2017, 20(2): 166-170.
[7]	郭波，王文静，赵凌宇, 等. Hsa-miR-106a在胃癌组织中的表达及其临床意义[J]. 山西医科大学学报, 2014, 45(1): 12-15.
[8]	Guan YX, Zhang MZ, Chen XZ, et al. LncRNA SNHG20 participated in proliferation, invasion and migration of breast cancer cells via miR-495[J]. J Cell Biochem, 2018, 119(10): 7971-7981.
[9]	Wang ZQ, He CY, Hu L, et al. Long noncoding RNA UCA1 promotes tumour metastasis by inducing GRK2 degradation in gastric cancer[J]. Cancer Lett, 2017, 408: 10-21.
[10]	Halimi M, Asghari SM, Sariri R, et al. Cellular response to ionizing radiation: A microRNA story[J]. Int J Mol Cell Med, 2012, 1(4): 178-184.
[11]	Berindan-Neagoe I, Monroig Pdel C, Pasculli B, et al. Micro-RNAome genome: A treasure for cancer diagnosis and therapy[J]. CA Cancer J Clin, 2014, 64(5): 311-336.
[12]	Baratieh Z, Khalaj Z, Honardoost MA, et al. Aberrant expression of PlncRNA-1 and TUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression[J]. Biomark Med, 2017, 11(12): 1077-1090.
[13]	窦越，王薇，唐勇. miR-145在胃癌中的表达及其意义[J]. 世界华人消化杂志, 2015, 511(35): 111-115.
[14]	Katsushima K, Natsume A, Ohka F, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment[J]. Nat Commun, 2016, 7: 13616.
[15]	申彤，司君利，崔京远, 等. 长链非编码RNA TUG1在胃癌患者中的表达及其对预后的影响[J]. 胃肠病学, 2017, 22(10): 588-591.

[1]	安杰, 牛云峰, 刘伟. LINC00520 通过miR-519b-3p/HIF1A 轴促进胃癌的侵袭转移[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 430-436.
[2]	李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[3]	陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[4]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5]	李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6]	刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7]	任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[8]	王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9]	陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[10]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[11]	刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[12]	许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[13]	贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[14]	黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[15]	张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Relationship of taurine up-regulated gene 1 and miRNA-145 in gastric cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Relationship of taurine up-regulated gene 1 and miRNA-145 in gastric cancer